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Abstract
Polyalanine expansions in transcription factors have been associated with eight distinct congenital human diseases. It is
thought that in each case the polyalanine expansion causes misfolding of the protein that abrogates protein function.
Misfolded proteins form aggregates when expressed in vitro; however, it is less clear whether aggregation is of relevance to
these diseases in vivo. To investigate this issue, we used targeted mutagenesis of embryonic stem (ES) cells to generate mice
with a polyalanine expansion mutation in Sox3 (Sox3-26ala) that is associated with X-linked Hypopituitarism (XH) in humans.
By investigating both ES cells and chimeric mice, we show that endogenous polyalanine expanded SOX3 does not form
protein aggregates in vivo but rather is present at dramatically reduced levels within the nucleus of mutant cells.
Importantly, the residual mutant protein of chimeric embryos is able to rescue a block in gastrulation but is not sufficient for
normal development of the hypothalamus, a region that is functionally compromised in Sox3 null embryos and individuals
with XH. Together, these data provide the first definitive example of a disease-relevant PA mutant protein that is both
nuclear and functional, thereby manifesting as a partial loss-of-function allele.
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Introduction
Trinucleotide repeat expansions are a relatively common cause
of human disease. The expanded trinucleotide can occur in an
untranslated region, for example in Fragile X syndrome in which a
CGG repeat adjacent to the FMRI promoter causes hypermethy-
lation and gene silencing. Alternatively repeat expansions can
occur in exonic regions and result in elongation of homopolymeric
amino acid tracts. For example polyglutamine (PQ) diseases such
as Huntingtons disease, are associated with long unstable PQ-
encoding stretches that lead to the production of a toxic species
and late onset disease characterised by the loss of a subset of
neurons. In addition to PQ encoding repeats, polyalanine (PA)
repeat expansion has recently emerged as a significant cause of
human disease. PA expansions have been linked to nine disorders
of which eight are congenital and one is late onset. Each is caused
by PA expansion in a separate gene, with the eight congenital
disorders linked to PA expansions in developmentally-important
transcription factors. These, and the associated disorders, are
SOX3 (X linked Hypopituitarism), HOXA13 (hand–foot–genital
syndrome), ARX (syndromic and non-syndromic X-linked mental
retardation), HOXD13 (synpolydactyly type II), PHOX2B (con-
genital central hypoventilation syndrome), FOXL2 (blepharophi-
mosis, ptosis and epicanthus inversus), ZIC2 (holoprosencephaly)
and RUNX2 (cleidocranial dysplasia). The ninth is the ubiquitous
RNA binding protein PABPN1 which is associated with the late
onset disease oculopharyngeal muscular dystrophy (OPMD).
Despite considerable functional analyses, the mechanism by
which PA expansion mutations cause disease is not completely
understood. Phenotype/genotype correlations in humans and
mouse models indicate that many PA alleles give rise to disease
phenotypes that resemble (HOXA13, FOXL2, ZIC2) or are less
severe (ARX) than null alleles, consistent with complete or partial
loss-of-function (LOF) [1,2,3,4]. In contrast, some PA alleles cause
similar but more severe disease phenotypes than null alleles
consistent with toxic gain-of-function (GOF) and/or dominant
negative activity (HOXD13, PHOX2B) [5,6]. Despite these
differences in mode of inheritance, all PA proteins behave very
similarly in vitro, such that over-expression in cell culture results in
the generation of cytoplasmic and/or nuclear aggregates, which
are likely to arise through protein misfolding [7,8,9]. While the
relevance of cellular aggregates to PA disease in general is unclear,
nuclear inclusions that contain mutant PAPBN1 protein are a
hallmark of OPMD [10], suggesting that aggregates may also form
in patients with PA expansion mutations in developmental
transcription factors. Protein aggregation also occurs in the related
polyglutamine (PQ) disorders where PQ expansion confers toxic
GOF [11,12]. Together, these data suggest that aggregate
formation may have a pathogenic role in PA disease alleles with
GOF activity. However, the critical question of whether aggre-
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gates form in vivo and, if so, how they may be implicated in the
pathogenesis of LOF PA diseases remains unresolved.
To investigate these issues, we used targeted mutagenesis of ES
cells to generate a 26 alanine PA tract expansion mutation in Sox3
(Sox3-26ala). The analogous human mutation causes X linked
Hypopituitarism (XH), a disease in which hemizygous males have
GH deficiency (resulting in short stature) and fully penetrant
intellectual disability [13]. Importantly, we find no evidence of
SOX3-26ala aggregate formation in neural derivatives of targeted
ES cells in vivo or in neurodifferentiated ES cell cultures. Instead,
the Sox3-26ala mutation leads to a massive reduction in SOX3
protein within the nucleus. We also present developmental and
biochemical evidence that residual mutant protein retains some
activity, indicating that Sox3-26ala functions as a partial LOF
allele.
Results/Discussion
In order to study the effects of disease-associated PA expansion
at a cellular level we created R1 ES cells with a targeted mutation
of Sox3. Homologous recombination was used to generate XY ES
cells carrying a 36 bp expansion in the first PA tract of Sox3,
extending the tract from 14 to 26 alanines (referred to hereafter as
Sox3-26ala ES cells; Figure 1). Morula injection of mutant ES cells
resulted in chimeras with up to 95% mutant cell contribution as
assessed by coat colour (Table 1). None of these chimeras
displayed any evidence of growth retardation (consistent with the
absence of short stature in heterozygous female carriers of the
human SOX3-26ala mutation who also contain a mixture of WT
and mutant cells, due to X inactivation [13]). However, despite
extensive breeding, none of these chimeras exhibited germline
transmission of the mutant allele. In contrast, germline compe-
tence was demonstrated with WT parental ES cells as well as a
clone carrying the PGK-Neo cassette without the PA tract
expansion (referred to hereafter as Neo ES cells). These data
suggest that the PA mutation in Sox3 had caused a block in male
fertility. This is consistent with a recently published report
demonstrating that Sox3 LOF in the germ cell lineage resulted in
an early defect in spermatogenesis and the lack of any reported
transmission of the human SOX3-26ala allele from hemizygous
males [13,14].
Since we were unable to transmit the Sox3-26ala mutation
through the male germline, the phenotypic consequences of the
mutation were initially investigated in Sox3-26ala ,-. WT
chimeric embryos. Immunostaining with a SOX3-specific anti-
body revealed a dramatic reduction in SOX3 protein in 13.5 dpc
telencephalic ventricular zone cells expressing the Sox3-26ala allele
(identified by NEO-immunoreactivity) in comparison to neigh-
bouring WT cells (Figure 2A). The ability of the antibody to detect
mutant protein was confirmed by staining COS-7 cells expressing
exogenous mouse Sox3-26ala, in which large peri-nuclear and
cytoplasmic aggregates were common (Figure S1). A striking
reduction in mutant SOX3 protein was also observed in 7.5 dpc,
9.5 dpc, 10.5 dpc and 11.5 dpc chimeras (Figure 3 and Figure S2)
indicating that this phenotype was not stage-dependent. High
power microscopy failed to detect any cytoplasmic or nuclear
aggregates of mutant protein but did reveal a very low level of
protein in the nucleus (Figure 2A). Comparison of Sox3-26ala and
Sox3-null embryonic CNS cells confirmed that the low level of
SOX3-26ala protein that we observed was not due to background
signal (Figure 2B). Mutant cells appeared morphologically normal
and there was no apoptotic induction as assessed by staining for
activated Caspase3 (Figure S3). To further characterise the cellular
phenotype of Sox3-26ala mutant cells, we performed neurodiffer-
entiation of Sox3-26ala ES cells (which are XY and therefore lack a
WT Sox3 allele). Immunohistochemical analysis confirmed the
overwhelming reduction of nuclear SOX3 protein in mutant
cultures (Figure 2C) in which the expression of other neural
progenitor markers were unaffected (data not shown). Rare cells
with near normal levels of nuclear mutant protein were also
detected but in no case was there evidence of protein aggregation
(Figure 2C). Western blot analysis further supported the near
complete loss of steady-state SOX3 protein levels in mutant cells
(Figure 2D). As triplet repeat expansion mutations have been
shown to affect mRNA transcription [12], we compared Sox3
message levels in WT and mutant cells in vitro and in vivo using
qPCR and in situ hybridisation, respectively (Figure 2E–2F). No
difference in Sox3 mRNA level was detected, indicating that the
massive reduction in SOX3 protein levels in the mutant cells has a
post-transcriptional aetiology and presumably occurs via degra-
dation of misfolded protein [8]. This was supported by in vitro
transcription/translation analysis which indicated that translation
of the mutant transcript was unaffected by the PA mutation
(Figure S4).
Taken together, these results indicate that Sox3-26ala is a LOF
allele and argue strongly against a role for aggregation in the
pathogenesis of XH. To further investigate LOF as the mechanism
of disease, we compared the development of the hypothalamus,
infundibulum and anterior pituitary in Sox3-26ala chimeric
embryos to Sox3 heterozygous embryos that carry a complete
LOF (null) allele. Sox3 +/2 embryos exhibit a defect in
infundibular development that results in aberrant induction and
bifurcation of the anterior pituitary primordium, Rathke’s Pouch
(RP) [15] accompanied by expansion of the floor of the ventral
diencephalon (Figure 3). Similar defects in infundibular morphol-
ogy and pituitary localisation have also been identified in XH
patients [16]. Importantly, 13.5 dpc and 11.5 dpc high percentage
Sox3-26ala ,-. WT chimeras exhibited dysmorphology of the
infundibulum, Rathke’s Pouch and ventral diencephalon that was
indistinguishable from Sox3+/2 embryos (Figure 3). These
abnormalities were also present in low percentage chimeras,
although were less severe consistent with the loss of SOX3
Author Summary
Alanine is one of the 20 amino acid building blocks from
which proteins are generated. Nearly 500 human proteins
contain stretches of consecutive alanine residues ranging
from 4 to 20 amino acids in length. Whilst the function of
these polyalanine (PA) tracts remains unknown, they are
interesting because DNA changes (mutations) that in-
crease their length above a threshold are responsible for
nine different human disorders. In vitro studies indicate
that expanded PA proteins misfold and aggregate,
suggesting that there may be a common ‘‘gain-of-
function’’ mechanism that underpins this group of
disorders. However, these data are difficult to reconcile
with genetic studies, which indicate that most PA
mutations cause protein loss-of-function. Therefore, to
investigate the pathological mechanism of PA disorders
we generated a mouse model of X-linked Hypopituitarism
(XH), a disease caused by PA expansion in the SOX3
protein. Strikingly, we found that the mouse version of the
disease-causing protein was almost completely cleared
from cells and that aggregates do not form in vivo. These
data explain why this type of mutation causes protein loss-
of-function and reveals why nature limits the length of PA
stretches.
Mouse Model of SOX3 Polyalanine Expansion Mutation
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Table 1. Failure of Sox3-26ala targeted ES clones to transmit through the germline.
Clone Number of chimeras
Percentage chimerism
(range) Number of pups born
Percentage of ES-derived pups
(agouti)
WT 15 5–100 50 18
Neo 4 50–90 35 49
Sox3-26ala-1 6 5–50 127 0
Sox3-26ala-2 4 60–90 81 0
Sox3-26ala-3 3 20–60 53 0
Sox3-26ala-4 4 75–95 156 0
doi:10.1371/journal.pgen.1003290.t001
Figure 1. Generation of Sox3-26ala ES cells. Scale representation of the Sox3 locus, targeting vector and recombinant alleles (A). Probing of BglII
digested DNA from ES cell clones with the 59 probe yielded an 8.8 kb fragment from the WT locus and a 5.9 kb fragment when the Neo cassette was
recombined into the Sox3 locus (Sox3-26ala or Neo). B) Representative Southern blot of 3 clones including a targeted clone (Sox3-26ala-3) is shown. C)
PCR using primers spanning the alanine expansion (red arrows in A) was used to distinguish whether targeted clones carried the expansion and gave
a 219 bp product instead of 186 bp as seen in WT.
doi:10.1371/journal.pgen.1003290.g001
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function being responsible for this phenotype. Notably, there was
an obvious reduction in SOX3 protein in mutant (NEO+) cells
thereby confirming that PA expansion has a functional impact in
neural cells that are directly implicated in XH pathology.
Having established that Sox3-26ala behaves as a LOF allele, we
next considered whether the low level of remnant SOX3 protein in
mutant cells was functional. To investigate this, we initially
performed transactivation assays in COS-7 cells using wild type
and mutant human and mouse SOX3 expression constructs and a
luciferase reporter containing four SOX consensus motif (SOCM)
binding sites. Both mouse and human SOX3-26ala proteins
showed activity in this assay that was significantly higher than
background (Figure 4A). However, consistent with previous
reports [7,16], this activity was much lower than WT SOX3
protein. To investigate whether this reduction was caused by lower
nuclear protein levels or an inherent defect in mutant protein
Figure 2. Transcription is unaffected but protein is cleared from mutant cells. A) SOX3 protein is present in every WT cell (NEO2) of the
13.5 dpc telencephalic ventricular zone but virtually absent from equivalent tissue derived from Sox3-26ala cells (NEO+). B) Comparison of SOX3
immunostaining on Sox3-null cells (from a 14.5 dpc +/2 embryo) and Sox3-26ala expressing cells (from a Sox3-26ala ,-. WT chimera) confirming
that the antibody is SOX3-specific and that the Sox3-26ala expressing cells exhibit a low level of residual nuclear protein. C) WT, Neo, Sox3-26ala and
Sox3-null ES cells were differentiated for 5 days in CDM as multi-cellular bodies. Rare SOX3 positive cells were detected in Sox3-26ala CDMs while the
majority of cells had low SOX3 protein levels in comparison to neighbouring WT CDM bodies processed on the same slide. D–E) WT, Neo, Sox3-26ala
and Sox3-null ES cells were grown in N2B27 for 4 days to form neural progenitors. Western blotting for SOX3 reveals a dramatic reduction of protein
in Sox3-26ala cells (D); 3 and 30 minute exposures are shown. E) Transcript levels of Sox3 are not affected in Sox3-26ala cells as determined by qPCR.
Three experimental replicates are shown. Data was normalised to Sox3 levels inSox3-Neo control cells and error bars represent SEM. F) ISH confirms
that Sox3 transcript is present at comparable levels in ventricular zone cells at 13.5 dpc derived from both WT (Neo2) and Sox3-26ala (Neo+) cells. ISH
performed on adjacent 10 mm coronal sections of 13.5 dpc chimeric telencephalon.
doi:10.1371/journal.pgen.1003290.g002
Mouse Model of SOX3 Polyalanine Expansion Mutation
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transactivation activity, we measured that relative amount of WT
and mutant SOX3 protein in the nucleus of transfected cells by
Western Blot (Figure 4B). We observed a reduction of similar
magnitude to the reduced luciferase output, suggesting that the
mutant protein that is present in the nucleus has similar activity to
WT. To investigate whether the residual nuclear SOX3-26ala
protein is functional in vivo we compared the phenotypes of 7.5 dpc
chimeras generated from either Sox3-null or Sox3-26ala ES cells, as
it has been reported that Sox3-null ES cell ,-. WT embryo
chimeras exhibit severe gastrulation defects [15]. As previous
analysis of Sox3-null ES cell chimeras was not performed with R1
ES cells (the parent line used to generate the 26ala mutant ES
cells), we generated R1 Sox3-null ES cells for this experiment.
Consistent with previous reports, a high proportion (52%) of Sox3-
null ES cell chimeras generated abnormal gastrulae (Figure 5). In
contrast, only 19% of Sox3-26ala ES cell,-.WT embryo 7.5 dpc
chimeras were morphologically abnormal which was not signifi-
cantly different to the proportion of abnormal chimeric embryos
generated using Sox3-flox control ES cells (Figure 5). Immuno-
staining of Sox3-26ala chimeras revealed a reduction in SOX3
protein levels that was similar to later embryonic stages (Figure
S1). These data indicate that nuclear SOX3-26ala protein is
functional in vivo and is sufficiently abundant to prevent overt
defects in gastrulation. We therefore conclude that Sox3-26ala is a
partial LOF allele.
This study represents the first investigation of the disease-
associated Sox3-26ala mutation under the control of the endog-
enous locus in a whole animal setting. The complete lack of
aggregates in SOX3 positive CNS zones (including the hypotha-
lamic-pituitary axis) provides strong evidence that aggregation is
Figure 3. Sox3-26ala cells cause pituitary defects indistinguishable from Sox3-null cells. WT, Sox3+/2 or Sox3-26ala,-.WT chimeras were
cut sagittally at 11.5 dpc (A) or 13.5 dpc (B) and immunostained for SOX3 and NEO expression. Percentage chimerism for each embryo in (A) and (B)
was determined by qPCR as outlined in the methods. ISH for Neo on adjacent sections at 11.5 dpc confirmed the identification of mutant cells within
the ventral diencephalon (A). Examples at 11.5 dpc show the infundibulum (I) appears unaffected in a 5% chimera, shallow in a 20% chimera and
absent in a 75% chimera that also displayed a Rathke’s Pouch (*) that had failed to detach from the oral ectoderm. At 13.5 dpc, heterozygous and
high percentage (65%) chimeric embryos displayed a distorted infundibulum (I) with a lobular edge (arrow heads) and a branched Rathke’s Pouch (*).
Low percentage chimeras (20%) look similar to WT (0%). C) Phase micrographs of 13.5 dpc coronal sections through the developing pituitary show a
broadening at the base of the third ventricle in chimeras (arrows). Chimerism for embryos shown in (C) was determined based on immunoreactivity
for NEO in adjacent sections (data not shown).
doi:10.1371/journal.pgen.1003290.g003
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not a feature of the human disease. In contrast, our data
demonstrate that PA expansion results in a dramatic reduction
in SOX3 protein due to a post-translational defect. Given that PA
expansion proteins co-localise with chaperones in vitro and that
aggregation is promoted by pharmacological inhibition of the
proteasome [8], it seems likely that mutant SOX3 protein misfolds
and is cleared from the cell. Of note, the small amount of protein
that remains translocates to the nucleus and is functionally active.
The level of protein that remains is sufficient for some
developmental contexts but not others (i.e. gastrulation but not
pituitary induction). This context-specific threshold of SOX3
activity may explain why XH patients with SOX3 PA mutations,
but not null mutations, have been identified.
In direct contrast to the Hoxd13 (+7ala) spdh spontaneous mouse
model in which mutant protein is mislocalised to the cytoplasm
[8], our data provide the first definitive example of a disease-
relevant PA mutant protein that is both nuclear and functional,
thereby manifesting as a partial LOF allele. Interestingly, mutant
protein levels in the Hoxa13 and Arx PA mouse models, which also
exhibit LOF inheritance, are diminished but not abolished by
western blot and whole mount immunodetection [1,17]. This
raises the possibility that nuclear localisation of suboptimal levels
of functional protein may be a feature of several PA diseases. In
the case of ARX, the PA mutant mouse model has been reported
to have normal nuclear localisation of mutant protein in some
tissues, but to have a reduction in the total number of positive cells
[17,18]. Given our data, an alternative interpretation is that cells
expressing ARX are not lost but are unable to be detected due to
misfolding and clearance of the mutant protein. In situ hybrid-
isation of Arx transcripts should provide a means of discriminating
between these possibilities.
In addition to SOX3-26ala, XH is also associated with a 7
alanine expansion mutation (SOX3-22ala) in the same polyalanine
tract [16,19,20]. Although SOX3-22ala is occasionally associated
with mild learning difficulties [20], it is interesting to note that the
infantile behaviour/severe MR that is fully penetrant in SOX3-
26ala-carrying males is not found in affected males with the SOX3-
22ala expansion mutation, suggesting that the shorter expansion is
less severe. Given our data showing a massive depletion of SOX3
protein in Sox3-26ala mutant cells in vivo, we would predict that
SOX3-22ala protein would also be reduced (compared to WT) but
to a lesser extent than the SOX3-26ala protein. This higher level
(and therefore activity) of SOX3-22ala compared to SOX3-26ala
would be sufficient for ‘‘cognitive’’ CNS development. Consistent
with this idea, the SOX3-22ala protein is less prone to aggregate
formation in cell culture [7,16], although one must be cautious in
Figure 4. SOX3-26ala from mouse and human retains transac-
tivation activity. A) COS-7 cells were transfected with pcDNA3.1
expression vector containing either mouse Sox3, human SOX3, mouse
Sox3-26ala, human SOX3-26ala or an empty vector control. Values
represent mean normalised luciferase values plus standard deviation of
four independent experiments measured 48 hours after transfection.
Student’s T-tests (two tailed, unequal variance) of SOX3-26ala from
human or mouse compared to empty vector control show a statistically
significant increase in luciferase activity. B) Nuclear protein lysates
prepared from duplicate plates 48 hours after transfection show that
less SOX3 is detected in the nucleus of cells expressing both mouse and
human SOX3-26ala. pcDNA3.1-EGFP transfected cells were used as a
control and prepared for both nuclear protein and whole cell extracts
(WCE). Blotting for Histone H3, indicates equal loading and blotting for
a-Tubulin shows an absence of cytoplasmic contamination in nuclear
preparations. Transfection efficiency was determined by co-transfecting
EGFP and counting positive cells prior to harvesting and found to be
equal for all plasmids.
doi:10.1371/journal.pgen.1003290.g004
Figure 5. Residual nuclear SOX3-26ala protein rescues a
gastrulation defect of Sox3-null ,-. WT chimeric embryos.
Sox3-26ala ,-. WT chimeras are normal at 7.5 dpc (gastrulation) unlike
Sox3-null,-.WT chimeras. A total of 15 Sox3-flox,-.WT ES chimeras,
31 Sox3-null,-. WT chimeras and 21 Sox3-26ala,-. WT chimeras
were blind scored by two independent operators as morphologically
normal or abnormal. The average score for each embryo was used to
plot the percentage of abnormal embryos for each condition and chi
squared analysis was performed with Sox3-flox,-. WT embryos used
to set expected outcomes. Significantly more Sox3-null,-. WT
chimeras were abnormal (p = 0.0001) while Sox3-26ala,-.WT chimeras
did not deviate from expected (p = 0.95). An example of normal
morphology is shown for Sox3-flox,-. WT and Sox3-26ala,-. WT
chimeras and an abnormal Sox3-null,-.WT chimera is also shown that
exhibits distortion of the ectodermal layer and apparent expansion of
cells at the primitive streak and the adjacent extra-embryonic region.
doi:10.1371/journal.pgen.1003290.g005
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interpreting pathological mechanism from over expression studies
in heterologous cell lines. While it would be useful to directly
compare SOX3-26ala and SOX3-22ala levels in vivo, a mouse
model of the SOX3-22ala mutation has not been generated.
However, given that it is now possible to generate neural
precursors directly from patients via iPS cells, it would be
interesting to compare the SOX3 protein levels in neuroprogeni-
tors derived from SOX3-22ala and SOX3-26ala carrying males.
This approach might also be informative for PA disorders in
general, particularly given that increased disease severity is
generally associated with longer PA expansions [21].
Based on these and other published data, we propose that both
GOF and LOF PA disease alleles are associated with a primary defect
in protein folding but that a critical difference in the capacity of cells
to clear mutant protein results in either the accumulation of
mislocalised cytoplasmic protein (GOF) or a diminished level of
functional nuclear protein (LOF). As indicated by earlier reports [21],
the former mechanism provides scope for dominant-negative and
toxic GOF through cytoplasmic sequestration of endogenous binding
partners. In the latter, we propose that misfolded protein is efficiently
cleared by the cell without significant perturbation of other cellular
processes, manifesting as LOF or partial LOF, depending on the
amount of residual functional protein. Factors that determine
whether or not a cell is able to efficiently clear the misfolded protein
could include the level of expression, local concentration differences
within the cell, the efficiency of the degradation pathway within
different affected cell types and the length of the PA expansion. We
propose that the aggregates seen when SOX3-26ala and all other PA
expansion proteins are expressed in vitro reflect the overloading of the
cell with mutant protein such that normal degradation pathways are
overwhelmed. Resolution of the factors that determine whether a cell
is able to clear or tolerate mutant protein will have broader
implications for proteinopathies such as Alzheimers Disease and
Huntingtons Disease in which only subsets of cells display
aggregation. For the future, it will be interesting to determine the
behaviour of mutant protein in other PA mouse models with GOF
and LOF inheritance and, where possible, in patient-derived induced
pluripotent stem (iPS) cell derivatives.
Methods
ES cell targeting
Sox3-26ala allele. The targeting vector was based on a Sox3-
Neo floxed vector published previously in which GFP and the loxP
sites were removed and a 36 bp insertion was introduced to the
existing 42 bp alanine encoding tract [15]. This was electroporat-
ed into 129 strain-derived (R1) mouse ES cells and 1000 G418
resistant clones were screened by Southern blotting. Integration at
the Sox3 locus was determined by a shift in a BglII fragment from
8.8 kb to 5.9 kb when probed with a 59Sox3 probe [15]. Clones
were subsequently screened for the alanine expansion using PCR
primers flanking the alanine tract; 59-AGACGCTGCTCAA-
GAAGGAC-39 and 59-CTGCACGAGCGAGTAGGC-39.
Clones targeted with the Neo cassette but lacking the Sox3-26ala
expansion were designated (Neo).
Null allele. The targeting vector for generation of the null
allele was the Sox3-Neo floxed vector published previously [15]. 400
clones were screened using the above probe and homologous
recombinants identified by a shift in the BglII fragment from 8.8 kb
to 7.5 kb. Two correctly targeted clones were transiently transfected
with a Cre recombinase expression plasmid (kind gift from Duncan
Hewett), seeded at clonal density and screened by PCR for the absence
of Sox3. Putative Sox3 null clones were confirmed by Southern blotting
(5 kb BglII fragment using the 59Sox3 probe, as above).
Chimera generation
129 derived ES clones were injected into c57/Bl6xB6D2F1
2.5 dpc morula, cultured overnight and transferred as blastocysts
into the uterus of 2.5 dpc pseudopregnant recipients.
ES cell culture and neurodifferentiation
R1 ES cells were maintained on irradiated MEFs in standard
conditions and neurodifferentiated either in aggregates in chem-
ically defined media as described in [22] referred to as (CDM) or
as monolayers as previously described [23], referred to as (N2B27).
qPCR gene expression and estimation of percentage
chimerism
RNA was prepared with Trizol (Invitrogen) and reverse
transcribed with a High Capacity RNA-to-cDNA kit (ABI). qPCR
was performed using Fast SYBRGreenMaster Mix (ABI) and run on
an ABI 7500 StepOnePlus system. Primer sequences and lengths of
amplified products were: Sox3 (117 bp) 59-GAACGCATCAGGT-
GAGAGAAG-39 and 59-GTCGGAGTGGTGCTCAGG-39, b-
Actin (89 bp) 59-CTGCCTGACGGCCAGG-39 and 59-GATTC-
CATACCCAAGAAGGAAGG-39. Sox3 expression was normalised
to b-Actin and expressed as relative quantity (RQ) using ABI software.
Embryonic chimerism was determined against a standard curve of
Sox3 dosage generated from adult gDNA of WT and Sox3-null mixed
0:100, 25:75, 50:50, 100:0. Loading was corrected using primers
against Sox1 (171 bp) 59-GACTTGCAGGCTATGTACAACATC-
39 and 59-CCTCTCAGACGGTGGAGTTATATT-39 and Ngn3
(120 bp) 59-CCCCAGAGACACAACAACCT-39 and 59-AGT-
CACCCACTTCTGCTTCG-39. Chimerism in Figure 2C was
estimated by NEO IF and ISH.
ISH and IF
Embryos were fixed in 4% PFA overnight and CDM bodies
were fixed for 15 minutes. Both were then equilibrated in 30%
sucrose overnight, set in OCT compound and cryosectioned on a
Leica CM1900 at 10 mm. ISH on fixed frozen sections was
performed using a Sox3 probe from a fragment generated with the
following primers; 59-AGCGCCTGGACACGTACAC-39 and 59-
AGCGCCTGGACACGTACAC-39 and a Neo probe from a
fragment amplified with the following primers; 59-GATC-
GATCCCCTCAGAAGAAC-39 and 59-GGCTATTCGGC-
TATGACTGG-39. Images were captured on a Zeiss Axiophot
upright microscope with AnalySIS software, using a 2.56 (Zeiss
Neofluar; NA0.5) or a 106 (Zeiss Neofluar; NA0.3) objective lens.
Primary antibodies and dilutions were goat anti-hSOX3 (R&D
#AF2569,1:150) and rabbit anti-NTPII (Millipore #06-747,
1:150). Imaging of IF was performed on a Zeiss Axioplan2
upright microscope with Axiovision software, using a 206 (Zeiss
Apochromat; NA0.75) or a 1006 (Zeiss Apochromat; NA1.3)
objective lens.
Western blotting
Day4 N2B27 neurodifferentiated ES cells were lysed in RIPA
buffer supplemented with protease inhibitors. SDS loading buffer
was added and the samples were resolved by 10% SDS-PAGE.
Duplicate gels were subjected to immunoblot analysis using anti-
hSOX3 (1:2500) and anti-a-Tubulin (Sigma #T8203, 1:2500)
antibodies since both detect proteins at ,40 kD. Signals were
developed using ECL substrate (West Pico, Pierce). For nuclear
protein lysates, cells were subjected to hypotonic lysis (10 mM
HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.4% NP-40, 10%
Ficoll-400, 1 mM DTT, 1 mM PMSF, 16 protease inhibitors),
centrifugation to pellet nuclei that were then washed in wash
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buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 150 mM KCl,
10% Ficoll-400, 1 mM DTT, 1 mM PMSF, 16 protease
inhibitors) and lysed in nuclear extract buffer (20 mM HEPES
pH 7.9, 1.5 mM MgCl2, 0.5 mM EDTA, 20% glycerol, 0.42 M
KCl, 1 mM DTT, 1 mM PMSF, 16 protease inhibitors).
Luciferase transcription assay
Transcriptional activities of mouse and human SOX3 and
SOX3-26ala were determined using the Dual-Luciferase Reporter
Assay System (Promega). 1.0 mg of plasmid DNA was transfected
into COS-7 cells using Lipofectamine according to manufacturer’s
instructions. All transfections were performed in triplicate and
contained luciferase reporter Sox Consensus Motif (SOCM;
46AACAAAG) [7], Renilla luciferase plasmid pRL-CMV and
one of pcDNA3.1, pcDNA3.1 hSOX3, pcDNA3.1 hSOX3-26ala,
pcDNA3.1 mSOX3 or pcDNA3.1 mSOX3-26ala expression
constructs (Promega). The firefly luciferase and Renilla luciferase
activities were determined after 48 h on a FluorStar Optima
(BMG technologies). Relative luciferase activity is the ratio of
firefly to Renilla normalised to pcDNA3.1. The assay was repeated
four times. Statistical analysis was performed using Student’s T-
test (two tailed, unequal variance).
Ethics statement
Animal experiments were approved by the University of Adelaide
Animal Ethics Committee. All studies were conducted in accordance
with the principles of animal replacement and reduction and
experimental refinement. Animals were monitored daily for evidence
of illness and, if distressed, were culled immediately by cervical
dislocation by an experienced investigator/animal technician.
Supplementary methods
Cell free transcription/translation. Cell free transcrip-
tion/translation was performed using the TnT Coupled Reticu-
locyte Lysate System (Promega, #L4610) as per manufacturer’s
instructions. Plasmids used were 250 ng of either pcDNA3.1
hSOX3, pcDNA3.1 hSOX3-26ala, pcDNA3.1 mSOX3 or
pcDNA3.1 mSOX3-26ala. Reactions were resolved on a Bio-
Rad 10% precast gel (#456-1033), transferred to PVDF mem-
brane, exposed to phosphor-screen and scanned.
COS-7 aggregation assay. COS-7 cells were grown on glass
coverslips, transfected with one of pcDNA3.1, pcDNA3.1 hSOX3,
pcDNA3.1 hSOX3-26ala, pcDNA3.1 mSOX3 or pcDNA3.1
mSOX3-26ala using Fugene6 (Roche) and stained with SOX3
antibody and DAPI two days later. At least 100 cells were scored
randomly from each condition. Results are shown as the mean of
three independent experiments and error bars represent one
standard deviation.
Supporting Information
Figure S1 Mutant SOX3-26ala protein aggregates in vitro. COS
cells were transfected with mouse or human pcDNA3.1 SOX3 or
pcDNA3.1 SOX3-26ala expression plasmids and two days later
cells were fixed and stained with a SOX3 antibody (Green) and
DAPI (Blue). Cells were scored according to the localisation of the
SOX3 staining as nuclear, cytoplasmic or peri-nuclear for which
representative examples are shown. At least 100 cells were scored
from each condition and the experiment was repeated three times.
Error bars show one standard deviation from the mean. Student’s
T-tests between WT and mutant for each category for both mouse
and human revealed statistically significant differences with a P
value of less than 0.05 in each case.
(TIF)
Figure S2 SOX3-26ala protein is cleared from neuroprogenitor
cells in vivo. Sox3-26ala,-.WT chimeras were cut at 7.5 dpc
(transverse section through neural groove), 9.5 dpc (transverse
section through neural tube) or 10.5 dpc (sagittal section through
ventral diencephalon) and stained with antibodies against SOX3
and NEO. Mutant Sox3-26ala cells (NEO positive cells; arrow
heads) have low SOX3 staining. Confocal microscopy was
performed for 7.5 dpc and 9.5 dpc embryos on a Leica SP5
spectral scanning confocal microscope with AnalySIS software and
a 1006(Leica HCL PL-APO; NA1.4) objective. 10.5 dpc embryos
were imaged using a Zeiss Axioplan 2 epifluorescence microscopy
as described in the methods.
(TIF)
Figure S3 SOX3-26ala expressing cells show no signs of
apoptosis. Coronal section of a 13.5 dpc Sox3-26ala,-.WT
chimera stained with antibodies against SOX3 and Activated
Caspase3 (BD Pharmingen, #559565, 1:1000). Boxed area in
overlay shows a rare Activated Caspase3 positive cell, while the
arrowhead indicates a patch of mutant cells (low SOX3) in which
no Activated Caspase3 positive cells are seen.
(TIF)
Figure S4 A) Phospor image of an in vitro transcription/
translation reaction of mouse and human SOX3 WT and 26ala
expression constructs. SOX3 protein of the expected size is
indicated by the arrow. Two strong bands were generated by the
mouse plasmids, possibly reflecting the inclusion of an upstream
ATG in the plasmid, while human plasmids generated only one
strong band at the expected size. SOX3-26ala for both mouse and
human runs slightly higher than WT protein reflecting the
expanded polyalanine tract. In addition, both mouse and human
SOX3-26ala have a high molecular weight species that appears to
be an aggregated form of SOX3 (*). (-) indicates no template
control. B) Immunoblotting using anti-SOX3 antibody (R&D
#AF2569) generates a near identical pattern to the phosphor
image in (A), thus confirming that the antibody is able to detect
mutant and wild type protein with comparable efficiency.
(TIF)
Acknowledgments
We thank Dr. Robin Lovell-Badge for providing Sox3-null mice and Alex
Janssan and Reuben Buckley for technical assistance.
Author Contributions
Conceived and designed the experiments: PT JH SP NR DM. Performed
the experiments: JH SP NR DM LR. Analyzed the data: JH PT SP NR
DM LR. Wrote the paper: PT JH.
References
1. Innis JW, Mortlock D, Chen Z, Ludwig M, Williams ME, et al. (2004)
Polyalanine expansion in HOXA13: three new affected families and the
molecular consequences in a mouse model. Hum Mol Genet 13: 2841–2851.
2. De Baere E, Beysen D, Oley C, Lorenz B, Cocquet J, et al. (2003) FOXL2 and
BPES: mutational hotspots, phenotypic variability, and revision of the genotype-
phenotype correlation. Am J Hum Genet 72: 478–487.
3. Roessler E, Lacbawan F, Dubourg C, Paulussen A, Herbergs J, et al. (2009) The
full spectrum of holoprosencephaly-associated mutations within the ZIC2 gene
in humans predicts loss-of-function as the predominant disease mechanism.
Hum Mutat 30: E541–554.
4. Shoubridge C, Fullston T, Gecz J (2010) ARX spectrum disorders: making
inroads into the molecular pathology. Hum Mutat 31: 889–900.
Mouse Model of SOX3 Polyalanine Expansion Mutation
PLOS Genetics | www.plosgenetics.org 8 March 2013 | Volume 9 | Issue 3 | e1003290
5. Brison N, Tylzanowski P, Debeer P (2011) Limb skeletal malformations - what
the HOX is going on? Eur J Med Genet 55: 1–7.
6. Dubreuil V, Ramanantsoa N, Trochet D, Vaubourg V, Amiel J, et al. (2008) A
human mutation in Phox2b causes lack of CO2 chemosensitivity, fatal central apnea,
and specific loss of parafacial neurons. Proc Natl Acad Sci U S A 105: 1067–1072.
7. Wong J, Farlie P, Holbert S, Lockhart P, Thomas PQ (2007) Polyalanine
expansion mutations in the X-linked hypopituitarism gene SOX3 result in
aggresome formation and impaired transactivation. Front Biosci 12: 2085–2095.
8. Albrecht AN, Kornak U, Boddrich A, Suring K, Robinson PN, et al. (2004) A
molecular pathogenesis for transcription factor associated poly-alanine tract
expansions. Hum Mol Genet 13: 2351–2359.
9. Nasrallah IM, Minarcik JC, Golden JA (2004) A polyalanine tract expansion in
Arx forms intranuclear inclusions and results in increased cell death. J Cell Biol
167: 411–416.
10. Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, et al. (2000) Nuclear
inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding
protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 9: 2321–
2328.
11. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. (1997)
Formation of neuronal intranuclear inclusions underlies the neurological
dysfunction in mice transgenic for the HD mutation. Cell 90: 537–548.
12. La Spada AR, Taylor JP (2010) Repeat expansion disease: progress and puzzles
in disease pathogenesis. Nat Rev Genet 11: 247–258.
13. Laumonnier F, Ronce N, Hamel BC, Thomas P, Lespinasse J, et al. (2002)
Transcription factor SOX3 is involved in X-linked mental retardation with
growth hormone deficiency. Am J Hum Genet 71: 1450–1455.
14. Laronda MM, Jameson JL (2011) Sox3 functions in a cell-autonomous manner
to regulate spermatogonial differentiation in mice. Endocrinology 152: 1606–
1615.
15. Rizzoti K, Brunelli S, Carmignac D, Thomas PQ, Robinson IC, et al. (2004)
SOX3 is required during the formation of the hypothalamo-pituitary axis. Nat
Genet 36: 247–255.
16. Woods KS, Cundall M, Turton J, Rizotti K, Mehta A, et al. (2005) Over- and
underdosage of SOX3 is associated with infundibular hypoplasia and
hypopituitarism. Am J Hum Genet 76: 833–849.
17. Kitamura K, Itou Y, Yanazawa M, Ohsawa M, Suzuki-Migishima R, et al.
(2009) Three human ARX mutations cause the lissencephaly-like and mental
retardation with epilepsy-like pleiotropic phenotypes in mice. Hum Mol Genet
18: 3708–3724.
18. Price MG, Yoo JW, Burgess DL, Deng F, Hrachovy RA, et al. (2009) A triplet
repeat expansion genetic mouse model of infantile spasms syndrome,
Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures,
and adult cognitive and behavioral impairment. J Neurosci 29: 8752–8763.
19. Burkitt Wright EM, Perveen R, Clayton PE, Hall CM, Costa T, et al. (2009) X-
linked isolated growth hormone deficiency: expanding the phenotypic spectrum
of SOX3 polyalanine tract expansions. Clin Dysmorphol 18: 218–221.
20. Alatzoglou KS, Kelberman D, Cowell CT, Palmer R, Arnhold IJ, et al. (2011)
Increased transactivation associated with SOX3 polyalanine tract deletion in a
patient with hypopituitarism. J Clin Endocrinol Metab 96: E685–690.
21. Albrecht A, Mundlos S (2005) The other trinucleotide repeat: polyalanine
expansion disorders. Curr Opin Genet Dev 15: 285–293.
22. Wataya T, Ando S, Muguruma K, Ikeda H, Watanabe K, et al. (2008)
Minimization of exogenous signals in ES cell culture induces rostral
hypothalamic differentiation. Proc Natl Acad Sci U S A 105: 11796–11801.
23. Ying QL, Stavridis M, Griffiths D, Li M, Smith A (2003) Conversion of
embryonic stem cells into neuroectodermal precursors in adherent monoculture.
Nat Biotechnol 21: 183–186.
Mouse Model of SOX3 Polyalanine Expansion Mutation
PLOS Genetics | www.plosgenetics.org 9 March 2013 | Volume 9 | Issue 3 | e1003290
